Profile data is unavailable for this security.
About the company
Oncodesign Precision Medicine SA is a France-based biopharmaceutical company specialized in precision medicine. It aims at providing effective diagnostic and therapeutic solutions for resistant and metastatic cancers. The Company’s technologies from Oncodesign, are OncoSNIPER for the selection of therapeutic targets using artificial intelligence; Nanocyclix for the design and selection of macrocyclic small molecule kinase inhibitors and Theranostics for the design and selection of radiolabeled biological molecules for systemic radiotherapy. It focuses on the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology.
- Revenue in EUR (TTM)468.73k
- Net income in EUR-7.78m
- Incorporated2020
- Employees19.00
- LocationOncodesign Precision Medicine Opm SA18 Rue Jean MazenDIJON 21000FranceFRA
- Websitehttps://www.oncodesign.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theranexus SA | 0.00 | -3.08m | 3.94m | 12.00 | -- | -- | -- | -- | -0.3971 | -0.3971 | 0.00 | -0.0004 | 0.00 | -- | -- | 0.00 | -50.35 | -42.66 | -64.95 | -47.97 | -- | -- | -- | -- | -- | -420.89 | 1.00 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
| Quantum Genomics SA | 0.00 | -9.40m | 5.03m | 3.00 | -- | -- | -- | -- | -0.1519 | -0.1519 | 0.00 | -0.0255 | 0.00 | -- | -- | 0.00 | -282.86 | -60.77 | -422.81 | -102.24 | -- | -3,548.91 | -- | -3,374.13 | -- | -131.78 | 3.97 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Acticor Biotech SA | 0.00 | -15.86m | 5.50m | 28.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.4011 | 0.00 | -- | -- | 0.00 | -129.36 | -- | -695.94 | -- | -- | -- | -- | -- | -- | -- | 3.71 | -- | -- | -- | -17.40 | -- | -- | -- |
| Poxel SA | 1.98m | -35.09m | 13.88m | 22.00 | -- | -- | -- | 7.01 | -1.08 | -1.08 | 0.0591 | -1.27 | 0.1002 | -- | 5.09 | 90,045.45 | -177.50 | -52.39 | -- | -92.20 | 0.0505 | -- | -1,771.33 | -299.15 | -- | -1.39 | -- | -- | 193.92 | -49.84 | -11.76 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 2.53m | 1.09m | 14.37m | 27.00 | 12.94 | -- | 9.11 | 5.67 | 0.9967 | 0.9967 | 2.32 | -- | -- | -- | -- | 93,777.41 | -- | -3.53 | -- | -4.39 | 110.03 | 134.21 | 43.01 | -33.16 | -- | 12.90 | -- | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Predilife SA | 317.79k | -4.22m | 14.50m | 19.00 | -- | -- | -- | 45.63 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Phaxiam Therapeutics SA | 2.14m | -21.92m | 17.62m | 54.00 | -- | 0.692 | -- | 8.23 | -3.46 | -3.46 | 0.3956 | 2.54 | 0.0409 | -- | 8.56 | 41,980.39 | -41.90 | -50.69 | -61.11 | -66.25 | -- | -- | -1,023.96 | -1,009.09 | -- | -70.91 | 0.4556 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Valbiotis SA | 527.00k | -8.94m | 18.23m | 52.00 | -- | 1.08 | -- | 34.59 | -0.6571 | -0.6571 | 0.0373 | 1.07 | 0.0208 | 2.52 | 0.2447 | 10,134.62 | -35.21 | -32.92 | -46.61 | -46.36 | -511.95 | 53.15 | -1,697.15 | -418.87 | 4.54 | -91.62 | 0.266 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Nfl Biosciences SAS | 0.00 | -2.37m | 19.41m | 4.00 | -- | 5.58 | -- | -- | -0.2653 | -0.2653 | 0.00 | 0.3584 | 0.00 | -- | -- | 0.00 | -44.70 | -83.27 | -70.88 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -53.28 | -- | -- | -- |
| Oncodesign Precision Medicine Opm SA | 468.73k | -7.78m | 19.65m | 19.00 | -- | 6.23 | -- | 41.91 | -0.449 | -0.449 | 0.0269 | 0.1733 | 0.0311 | -- | 0.4553 | 21,305.91 | -51.68 | -- | -85.27 | -- | 153.18 | -- | -1,660.23 | -- | -- | -360.87 | 0.715 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Fermentalg SA | 8.04m | -14.14m | 26.28m | 58.00 | -- | 0.685 | -- | 3.27 | -0.2787 | -0.2787 | 0.1521 | 0.4452 | 0.1395 | 1.34 | 4.82 | 129,629.00 | -22.80 | -21.94 | -25.70 | -24.71 | 14.04 | 14.73 | -163.46 | -248.95 | 3.42 | -53.95 | 0.2639 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
Data as of Nov 13 2024. Currency figures normalised to Oncodesign Precision Medicine Opm SA's reporting currency: Euro EUR
1.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| OFI Invest Asset Management SAas of 29 Aug 2024 | 158.04k | 0.87% |
| Claresco Finance SAas of 30 Jun 2024 | 71.08k | 0.39% |
Data from 30 Jun 2024 - 30 Oct 2024Source: FactSet Research Systems Inc.
